CII
ALXN

CR Intrinsic Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

CR Intrinsic Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,000
Closed -$1.16M – 388
2013
Q3 		$1.16M Sell
10,000
-56,001
-85% -$6.14M 0.04% 314
2013
Q2 		$6.09M Buy
+66,001
New +$6.36M 0.21% 161

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CR Intrinsic Investors's ALXN Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2013, closing a stake of 10,000 shares — an estimated $1.16M sold.

CR Intrinsic Investors first reported a position in ALXN in Q2 2013 and held it in 2 quarters. The position peaked at $6.09M in Q2 2013. 463 funds tracked by Wall St. Rank hold ALXN as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Alexion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 10,000 Alexion Pharmaceuticals shares in Q4 2013, an estimated $1.16M.
  • CR Intrinsic Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • CR Intrinsic Investors's Alexion Pharmaceuticals position peaked at $6.09M in Q2 2013.
  • 463 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.